Bioethics Debate: Ethics of U Penn Surgical “Drug Implant” Experiment This debate between AHRP President, Vera Sharav and Bioethicist, Paul Root Volpe, Ph.D., University of Pennsylvania, was prompted by an October 7 infomail. The reasons for AHRP’s opposition to drug implants for psychiatric patients are explained here: https://ahrp.org/ahrpspeaks/drugimplant1103.php —–Original Message—–…
Eli Lilly Wants Insurers to Pay $1 billion in Zyprexa claims – AP Tue, 13 Sep 2005 The Associated Press reported that Eli Lilly is trying to pass the buck to insurers– In addition to the $700 million Lilly agreed to pay to settle a lawsuit over the company having…
Philadelphia Daily News Pharma Influence: Penn Psychiatrist Files Whistleblower Lawsuit – Investigtion Confirms Medicare Chief Lied to Congress Wed, 7 Jul 2004 “Drug companies not only write checks to hospitals, they write checks to politicians…They write checks to both sides of the aisle.” Two separate news reports provide a glimpse…
Next Phase in Psychiatry? Or, NIMH Effort to Rescue Bad Drugs – WSJ Fri, 29 Jul 2005 The Wall Street Journal uncritically reported: “The results of the largest studies ever conducted of depression and schizophrenia will be released in coming months, potentially transforming the way patients are treated and shaking…
Lilly to Add Suicide Warning to Strattera – Medicaid May shrink $5.5 Billion spending on Schizophrenia Drug Thu, 29 Sep 2005 Reuters reports that Eli Lilly is adding a Black Box suicide warning to the Strattera label. Strattera has been promoted as a “non stimulant” treatment for ADHD. Since ADHD…
ALLIANCE FOR HUMAN RESEARCH PROTECTION* (AHRP) April 10, 2000 Gary Ellis, Ph.D, Director Michael A. Carome, M.D. Chief Compliance Oversight Branch Division of Human Subject Protections Office of Protection from Research Risks Rockville, MD 20892-7507 Re: High Risk Experiment With Children Who Have No Medical Diagnosis Dear Dr. Ellis &…
Merck / Johnson & Johnson/ Lilly-Zyprexa: $690 Million settlement / a Flowering of Diabetes Drugs Fri, 10 Jun 2005 A cluster of news reports about three pillars of the pharmaceutical industry– Merck, Eli Lilly, and Johnson & Johnson–leave no doubt that this industry has shown its disregard for the welfare…
Janssen Pharma Admits Hiding Risperdal Drug Risks / TMAP & Illinois Mental Health Screening Plan Sat, 24 Jul 2004 The Miami Herald reports (below) that in a letter to doctors, Janssen Pharmacia, manufacturer of the highly promoted drug, Risperdal (risperidone), admitted “misleading doctors and other healthcare providers about the safety…
 THE ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) https://ahrp.org 142 West End Ave. Suite 28P New York, NY 10023 Testimony by The Alliance for Human Research Protection Committee on Ways and Means Hearing on Protections for Foster Children Enrolled in Clinical Trials May 18, 2005 On March 10, 2004, The ALLIANCE…
Failed Drug Treatments for Schizophrenia–Letters to the Editor – NYT Fri, 23 Sep 2005 Letters to the NY Times editor (below) demonstrate the combative reaction of stakeholders in the psychotropic drug industry to the evidence-based overthrow of psychiatry’s treatment recommendations. Psychiatrists who have financial contracts with psychotropic drug manfuacturers, have…
Risks: Drugs / Vaccines / Trials / Treatment Evidence of antidepressant harm Oct 14, 2005: Andrew Finkelstein Letter to Dr. Russell Katz, Director, Neuropharmacological Drug Products, FDA about FDA’s Failure to Warn about Neurontin-Suicides Aug 29: FDA Response to Utah Court Must Be Truthful Re: Zoloft / SSRI Suicidal Risks…
Merck Baby Vaccines Not Pure – LAT/ FDA Advisory-Crestor / Zyprexa Lawsuit charges Lilly concealed Diabetes risk Fri, 11 Mar 2005 The FDA’s failure to carry out its watchdog responsibility to protect the public from unsafe drugs, has encouraged the pharmaceutical industry to conceal the risks and deceive the public….
